Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYi L. HwaDDDavid Dingli

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows 61% overall response rate and 93% 2-year overall survival in patients with relapsed multiple myeloma, highlighting safety of oral regimen.

Key Points

  • Overall response rate reached 61%, with 21% achieving complete response in relapsed multiple myeloma.
  • Median progression-free survival was 24 months, with a notable 2-year overall survival rate of 93%.
  • Single arm, phase 2 study assessed the all-oral regimen of selinexor, pomalidomide, and dexamethasone for safety and efficacy.
  • The regimen demonstrates effective treatment with manageable toxicity, supporting further trials to confirm findings.

Cite This Study

Hwa et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df58https://doi.org/10.1182/blood-2025-2281
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study2025
  2. 2Safety and efficacy of first-line selinexor plus bortezomib, lenalidomide and dexamethasone (XVRd) in high risk newly diagnosed multiple myeloma: A multi-center, single-arm, phase ib/II trial2025
  3. 3Efficacy and safety of selinexor combined with VRD in newly diagnosed multiple myeloma with EMD: a phase 2 trial2026 · 2 citations
  4. 4A novel conditioning regimen combining selinexor with melphalan Improves Survival in Patients with multiple myeloma:a prospective study2025
  5. 5Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)2025 · 3 citations